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INTRODUCTION 
ANALYTICAL CHEMISTRY 
Analytical chemistry is defined as the science and art of developing sensitive, reliable 
and accurate method for determining the composition of materials in terms of elements or 
compounds which they contain. Pharmaceutical analysis comprises those procedures 
necessary to determine the identity, strength, quality and purity of drug and chemicals 
Pharmaceutical analysis deals mainly with bulk materials, dosage forms and more recently, 
biological samples in support of bio-pharmaceutical and pharmacokinetic studies. 
Pharmaceutical analysts in research and development (R&D) of  pharmaceutical 
industry plays a very comprehensive role in new drug development and follow up activities to 
assure that a new drug product meets the established standards, its stability and continued to 
meet the purported quality throughout its shelf life. The different activity of R&D includes 
drug development, (synthesis and manufacture), formulation, clinical trials, evaluations and 
finally launching i.e. finished products. Closely associated with these are regulatory and 
quality assurance functions.(Jary D.Chiristan 5th Edition) 
CHROMATOGRAPHY AND ITS TYPES 
A variety of analytical techniques such as spectroscopy (UV-Visible), gas 
chromatography (GC), high performance liquid chromatography (HPLC),Ultra performance 
liquid chromatography (UPLC) supercritical fluid chromatography (SFC), capillary 
electrophoresis (CE) coupled with selective detectors (diode-array detector (DAD) and mass 
spectrometry (MS)) are frequently used to achieve the above requirements 
Chapter 1                                                                                                                              Introduction 
 
 
J.K.K.M.M.R.F college of Pharmacy                                                    Dept of Pharmaceutical Analysis 
2 
 
In spite of various techniques available, HPLC and UPLC has become a universal tool 
for pharmaceutical and biomedical research, as well as product analysis. The availability of 
fully automated systems, excellent quantitative precision, accuracy, sensitivity, selectivity, 
increased selection of column stationary phases, applicability to a broad variety of sample 
matrices and ability to hyphenate with several spectroscopic detectors has made HPLC or 
UPLC the instrument of choice for the analysis of most categories of drugs. 
Similarly, HPLC or UPLC methods are abundantly used in the field of biomedical 
analysis, viz. therapeutic drug monitoring, pharmacokinetic and bioequivalence studies. The 
assay of drugs in blood, plasma and tissues presents analytical challenges. The drug 
substance is typically present at low concentrations, bound to proteinaceous material and 
endogenous compounds typically present in the samples can interfere with the analysis. For 
these reasons, the analytical methods usually be highly sensitive to detect analytes at low 
concentrations and required a sample pretreatment procedure such as liquid-liquid extraction 
(LLE) or solid phase extraction (SPE), to isolate the analyte from the complex biological 
matrix. Hence, high sensitivity and automation of sample processing tools to deal with large 
number of samples are strong incentives for the consideration of HPLC or UPLC methods in 
biomedical analysis. 
The number of drugs introduced into the market is increasing every year, these drugs may be 
either new entities or partial structural modifications of the existing ones. Very often, there is 
a time lag from the date of introduction of a drug into the market to the date of its inclusion in 
the pharmacopoeias. This happens because of the possible uncertainties in the continuous and 
wider usage of these drugs, reports of new toxicities (resulting in their withdrawal from the 
market), development of patient resistance and introduction of better drugs by competitors. 
Under these conditions, standards and analytical procedures for thesedrugs may not be 
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available in pharmacopoeias. It becomes necessary, therefore, to develop newer analytical 
methods for such drugs.  
UPLC comes from HPLC .Ultra Performance Liquid Chromatography (UPLC) is a relatively 
new technique giving new possibilities in liquidchromatography, especially concerning 
decrease of time and solvent consumption.This enhanced the demand for UPLC methods for 
the simultaneous determination of drugs in pharmaceutical mixtures. 
INTRODUCTION TO HIGH PERFORMANCE LC 
 
The acronym HPLC, coined by the late Prof.Csaba Horvath for his 1970 Pittcon 
paper,originally indicated the fact that high pressure was used to generate the flow required 
forliquid chromatography in packed columns. In the beginning, pumps only had a 
pressurecapability of 500 psi. This was called high pressure liquid chromatography, or 
HPLC.  (Gurdeep RChathwal, Sham K Anand, 2.624-2-631) 
The early 1970s saw a tremendous leap in technology. These new HPLC instruments could 
develop up to 6,000 psi of pressure, and incorporated improved injectors, detectors, and 
columns. HPLC really began to take hold in the mid-to late-1970s. With continued advances 
in performance during this time (smaller particles, even higher pressure), the acronym HPLC 
remained the same, but the name was changed to high performance liquid chromatography.  
 
Figure 1 High-Performance Liquid Chromatography [HPLC] System 
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High performance liquid chromatography is now one of the most powerful tools in analytical 
chemistry. It has the ability to separate, identify, and quantitate the compounds that are 
present in any sample that can be dissolved in a liquid. Today, compounds in trace 
concentrations as low as parts per trillion (ppt) may easily be identified. HPLC can be, and 
has been, applied to just about any sample, such as pharmaceuticals, food, nutraceuticals, 
cosmetics, environmental matrices, forensic samples, and industrial chemicals. The 
components of a basic high-performance liquid chromatography (HPLC)system are shown in 
the simple diagram in Figure 1 . 
A reservoir (Solvent Delivery) holds the solvent (called the mobile phase, because it moves). 
A high-pressure pump solvent manager is used to generate and meter a specified flow rate of 
mobile phase, typically millilitres per minute.   
An injector (sample manager or auto sampler) is able to introduce (inject) the sample into the 
continuously flowing mobile phase stream that carries the sample into the HPLC column. The 
column contains the chromatographic packing material needed to effect the separation. This 
packing material is called the stationary phase because it is held in place by the column 
hardware. A detector is needed to see the separated compound bands as they elute from the 
HPLC column (most compounds have no color, so we cannot see them with our eyes).   
The mobile phase exits the detector and can be sent to waste, or collected, as desired. When 
the mobile phase contains a separated compound band, HPLC provides the ability to collect 
this fraction of the eluate containing that purified compound for further study. This is called 
preparative chromatography. The high-pressure tubing and fittings are used to interconnect 
the pump, injector, column, and detector components to form the conduit for the mobile 
phase, sample, and separated compound bands.   
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The detector is wired to the computer data station, the HPLC system component that 
records the electrical signal needed to generate the chromatogram on its display and to 
identify and quantitate the concentration of the sample constituents. Since sample compound 
characteristics can be very different, several types of detectors have been developed. For 
example, if a compound can absorb ultraviolet light, a UV-absorbance detector is used. If the 
compound fluoresces, a fluorescence detector is used. If the compound does not have either 
of these characteristics, a more universal type of detector is used, such as an evaporative-
light-scattering detector (ELSD). The most powerful approach is the use multiple detectors in 
series. For example, a UV and/or ELSD detector may be used in combination with a mass 
spectrometer (MS) to analyse the results of the chromatographic separation. This provides, 
from a single injection, more comprehensive information about an analyse. The practice of 
coupling a mass spectrometer to an HPLC system is called LC/MS. 
 INTRODUCTION TO ULTRA PERFORMANCE  LIQUID CHROMATOGRAPHY 
 
In 2004, further advances in instrumentation and column technology were made to 
achieve very significant increases in resolution, speed, and sensitivity in liquid 
chromatography. Columns with smaller particles (1.7 micron) and instrumentation with 
specialized capabilities designed to deliver mobile phase at 15,000 psi (1,000 bars) were 
needed to achieve a new level of performance. A new system had to be holistically created to 
perform ultra-performance liquid chromatography, now known as UPLC technology.  
Basic research is being conducted today by scientists working with columns containing even 
smaller 1-micron-diameter particles and instrumentation capable of performing at100,000 psi. 
This provides a glimpse of what we may expect in the future. UPLC refers to Ultra 
Performance Liquid Chromatography. It improves in three areas: chromatographic resolution, 
speed and sensitivity analysis. It uses fine particles and saves time and reduces solvent 
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consumption . UPLC is comes from HPLC. HPLC has been the evolution of the packing 
materials used to effect the separation. An underlying principle of HPLC dictates that as 
column packing particle size decreases, efficiency and thus resolution also increases. As 
particle size decreases to less than 2.5µm, there is a significant gain in efficiency and it’s 
doesn’t diminish at increased linear velocities or flow rates according to the common Van 
Demeter equation . By using smaller 
particles, speed and peak capacity (number of peaks resolved per unit time) can be extended 
to new limits which is known as Ultra Performance. 
The classic separation method is of HPLC (High Performance Liquid 
Chromatography) with many advantages like robustness, ease of use, good selectivity and 
adjustable sensitivity. Its main limitation is the lack of efficiency compared to gas 
chromatography or the capillary electrophoresis due to low diffusion coefficients in liquid 
phase, involving slow diffusion of analyses in the stationary phase. The Van Demeter 
equation shows that efficiency increases with the use of smaller size particles but this leads to 
a rapid increase in back pressure, while most of the HPLC system can operate only up to 400 
bar. That is why short columns filled with particles of about 2µm are used with these 
systems, to accelerate the analysis without loss of efficiency, while maintaining an acceptable 
loss of load.  
To improve the efficiency of HPLC separations, the following can be done,  
(1) Work at higher temperatures   
(2) Use of monolithic columns Swatrz M.E 2005 
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METHOD DEVELOPMENT AND OPTIMIZATION OF CHROMATOGRAPHIC 
CONDITIONS 
Methods for analysing drugs in multi component dosage forms can be developed if 
the nature of the sample, namely, its molecular weight, polarity, ionic character and the 
solubility parameter are in hand. Until and unless considerable trial and error procedures have 
not performed, an exact recipe for HPLC cannot be provided. The most difficult problem 
usually is where to start, what type of column is worth trying with what kind of mobile phase. 
In general one begins with reversed phase chromatography, when the compounds are 
hydrophilic in nature with many polar groups and are water soluble.(Skoog et al 2005). 
 
Selection of stationary phase/ column: 
 Selection of the column is the initial and the most noteworthy step in method 
development. The proper choice of separation column includes three different approaches. 1. 
Selection of separation system 2. The particle size and the nature of the column packing3. 
The physical parameters of the column i.e. the length and the diameter. Some of the crucial 
parameters considered while selecting chromatographic Columns. They are length and 
diameter of the column, packing material, Shape of the particle, Size of the particles, % of 
Carbon loading, Pore volume, Surface area and End capping. The column is selected 
depending on the nature of the solute and the information about the analyse. Reversed phase 
mode of chromatography facilitates information about the analyse. Reversed phase mode of 
chromatography facilitates a wide range of columns like dimethyl silane (C2), butyls lane 
(C4), octylsilane (C8), octadecylsilane (C18), base deactivated silane (C18) BDS, cyan 
propyl(CN), nitro, amino etc. 
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Selection of mobile phase: 
The primary objective in selection and optimization of mobile phase is to achieve 
optimum separation of all the individual impurities and degrades from one other and from 
analyse peak. In liquid chromatography, the solute retention is governed by the solute 
distribution factor, which reflects the different interactions of the solute-stationary phase, 
solute-mobile phase and the mobile phase-stationary phase. For a given stationary phase, the 
retention of the given solute depends directly upon the mobile phase, the nature and the 
composition of which has to be judiciously selected in order to get appropriate and required 
solute retention. The mobile phase has to be adapted in terms of elution strength (solute 
retention) and solvent selectivity (solute separation). Solvent polarity is the key word in 
chromatographic separations since a polar mobile phase will give rise to low solute retention 
in normal phase and high solute retention in reverse phase LC. The selectivity will be 
particularly altered if the buffer pH is close to the pKa of the analytes; the solvent strength is 
a measure of its ability to pull analyte from the column. It is generally controlled by the 
concentration of the solvent with the highest strength. Buffer, pH of the buffer ,mobile phase 
composition are the parameters, which shall be taken into consideration while selecting and 
optimizing the mobile phase. Firstly, Buffer and its strength play an important role in 
deciding the peak symmetries and separations. Some of the most, commonly employed 
buffers are Phosphate buffer (Potassium dihydrogen phosphate, Dipotasium hydrogen 
phosphate, Sodium dihydrogen phosphate, Disodium hydrogen phosphate), Phosphoric acid 
buffers prepared using O-Phosphoric acid, Acetate buffers (Ammonium acetate, Sodium 
acetate) and Acetic acid buffers prepared using acetic acid. The retention time also depends 
on the molar strengths of the buffer. Molar strength is increasingly proportional to retention 
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times. The strength of the buffer can be increased, if necessary, to achieve the required 
separations. The solvent strength is a measure of its ability to pull analytes from the column. 
It is generally controlled by the concentration of the solvent with the highest strength. 
 Secondly, pH plays an important role in achieving the chromatographic separations 
asit controls the elution properties by controlling the ionization characteristics. Experiments 
were conducted using buffers having different pH to obtain the required separations. It is 
important to maintain the pH of the mobile phase in the range of 2.0 to8.0 as most columns 
does not withstand the pH which are outside this range. Thisis due to the fact that the siloxane 
linkage area gets cleaved below pH 2.0, whilepH valued above 8.0 silica may dissolve. 
Finally, by choosing the optimum mobile phase composition most of the 
chromatographic separations can be achieved This is due to the fact that fairly large amount 
of selectivity can be achieved by choosing the qualitative and quantitative composition of 
aqueous and organic portions. Most widely used solvents in reverse phase chromatography 
are methanol and acetonitrile. Experiments were conducted with mobile phases having 
buffers with different pH and different organic phases to check for the best separations 
between the impurities. A mobile phase which gives separation of all the impurities and 
degrades from the analyte peak and which is rugged with variations of both aqueous and 
organic phase by at least ±0.2%. 
The low solubility of the sample in the mobile phase can also cause bad peak shapes. 
It is always advisable to use the same solvents for the preparation of sample solution for the 
preparation of sample solution as the mobile phase to avoid precipitation of the compounds in 
the column injector. 
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Optimizations are often started only after a reasonable chromatogram has been 
obtained. A reasonable chromatogram means that more or less symmetrical peaks on the 
chromatogram detect all the compounds. By slight modification of the mobile phase 
composition, the position of the peaks can be predicted within the range of investigated 
changes. An optimized chromatogram is the one in which all the peaks are symmetrical and 
are well separated in less run time. 
VALIDATION 
The word “validation” means “Assessment” of validity or action of validity or action 
of providing effectiveness’. 
Definitions 
FDA defines validation as “establish the documented evidence which provides a high 
of assurance that a specific process will consistently produce a product of predetermined 
specifications and quantity attributes”. 
 WHO action of providing that, any procedure, process, equipment, material, activity, 
or system actually leads to the expected results. 
EUMGP define validation as “action of proving in accordance with the principle of 
Good manufacturing practice (GMP), that any material, activity or system actually lead to 
expected result”.  
AUSTRALIANGMP defines validation as “the action of proving that any material, 
process, activity, procedure, system, equipment or mechanism and intended results”. 
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METHOD VALIDATION GUIDELINES 
Regulatory agencies such as the International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), the Food 
and Drug Administration (FDA) and the United States Pharmacopoeia (USP) in the European 
community, Japan and United States have published a number of guidelines to assist 
pharmaceutical companies in validation of analytical methods for drug substances. 
 
FDA guidelines 
The FDA published the draft on “Guidance for Industry on Analytical Procedures and 
Method Validation” to aid pharmaceutical companies in meeting the code of federal 
regulations requirement [FDA, 2000]. This guidance, when approved, supersedes the FDA 
Guidance for Industry on Submitting Samples and Analytical Data for Method Validation 
[FDA, 1987]. According to the FDA, analytical methods are categorized into four tests: 
identification, testing for impurities (quantitative and limit), assay (dissolution, content, 
potency), and specific tests. Depending on the type of test, different validation requirements 
may apply because method validation requirements are directly related to the purpose of the 
analytical procedure. Recently, the Centre for Drug Evaluation and Research (CDER), a 
division of the FDA, also issued guidance for validation of bio analytical methods [FDA-
CDER, 2001]. 
ICH guidelines  
The ICH was initiated around 1990. It is an important regulatory initiative to 
standardize regulatory requirements between the European Community, Japan and the United 
States. Recognizing the benefits of having consistent international requirements, ICH 
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developed a number of guidelines that have been recognized in these countries. The two main 
documents of ICH guidelines pertaining to analytical method validation are: 
(i) Q2A: Text on Validation of Analytical Procedures [ICH-Q2A, 1995] 
(ii) Q2B: Validation of Analytical Procedure Methodology [ICH-Q2B, 1997] 
USP guidelines 
The USP [USP, 2006] categorizes analytical methods into four types of tests: 
quantitation of major components of drug product, testing for impurities (quantitative and 
limit), performance characteristics and identification tests. USP refers to the same definitions 
of ICH Q2A and Q2B recommendations for procedures on meeting validation requirements. 
The difference in USP and ICH terminology is for the most part one of semantics; however, 
there is one notable exception. ICH treats system suitability as a part of method validation, 
whereas the USP treats it in a separate chapter (621). 
Table 1 Comparison of validation parameters required for HPLC assay methods 
ICH Guidelines                USP Guidelines FDA Guidelines 
Accuracy Accuracy Accuracy 
Precision Precision Precision 
Repeatability -- Repeatability 
Inter-day precision -- Inter-day precision 
Reproducibility -- Reproducibility 
Specificity Specificity Specificity 
Limit of detection Limit of detection Limit of detection 
Limit of quantification Limit of quantification Limit of quantification 
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Linearity Linearity Linearity 
Range Range Range 
-- Ruggedness -- 
Robustness Robustness Robustness 
System suitability System suitability System suitability 
 
Analytical method validation 
Method validation is the process for establishing that performance characteristics of 
the analytical method are suitable for the intended application. Chromatographic methods 
need to be validation before first routine use. To obtain the most accurate results, all of the 
variables of the method should be considered, including sampling procedure, sample 
preparation, chromatographic separation, detection and data evaluation, using the same 
matrix as that of the intended sample. The validity of an analytical method can only be 
verified by laboratory studies. All validation experiments used to make claims or conclusions 
about validity of the method should be documented in report. 
Types of analytical procedures to be validated  
 Identification test for impurities 
 Quantitative test for impurities 
 Limit test control of impurities 
 Quantitative test for the active moiety in samples of drug substance or drug product, 
or other selected components (s) in the drug product.  
 Dissolution testing.  
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VALIDATION PARAMETERS AS PER ICH & FDA GUIDELINES 
(i) Accuracy 
 The accuracy of an analytical procedure expresses the closeness of agreement 
between the value, which is accepted either as a conventional true value or an accepted 
reference value and the value found.  
The accuracy may be determined by application of analytical method to an analyte of 
known purity (example: reference standard) and also by comparing the results of the method 
with those obtained using an alternate procedure that has been already validated. 
The true value for accuracy assessment can be obtained in several ways and the value 
found as: 
One method is to compare the results of the method with results from an established 
reference method. This approach assumes that the uncertainty of the reference method is 
known. 
Secondly, accuracy can be assessed by analyzing a sample with known concentrations 
and comparing the measured value with the true value as supplied with the material. 
Third method if certified reference materials or control samples are not available, a 
blank sample matrix of interest can be spiked with a known concentration by weight or 
volume. After extraction of the analytic from the matrix and injection into the analytical 
instrument, its recovery can be determined by comparing the response of the extract with the 
response of the reference material dissolved in a pure solvent. Because this accuracy 
assessment measures the effectiveness of sample preparation, care should be taken to mimic 
the actual sample preparation as closely as possible.  At each recommended level studied, 
replicate samples are evaluated. Accuracy should be assessed using a minimum of 9 
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determinations over a minimum of 3 concentrations (3 replicates each of the total analytical 
procedure). Accuracy studies for drug substance and drug product are recommended to be 
performed at the 80, 100 and 120% levels of label claim as stated in the Guidance for 
submitting samples and analytical data for methods Validation and as well the accuracy 
should be within the range 98-102%.  
(ii) Precision 
 The precision of an analytical procedure expresses the closeness of agreement 
between a series of measurement obtained from multiple sampling of the same homogenous 
sample under the prescribed conditions. Precision of an analytical procedure is usually 
expressed the variance, standard deviation of coefficient of variation of a series of 
measurement. 
Precision may be considered at three levels: repeatability, intermediate precision and 
reproducibility. Precision should be investigated using homogeneous, authentic samples. 
However, if it is not possible to obtain a homogeneous sample it may be investigated using 
artificially prepared samples or a sample solution. 
For a good method precision, the intra-day and inter-day precisions should be within 
the acceptance criteria of % RSD ≤2.0.respectively.  
(iii)  Specificity   
Specificity is the ability to assess unequivocally the analyte in the presence of 
components, which may be expected to be present. Typically, these might include impurities, 
degrades, matrix, etc. For formulation assay, a sample matrix may include impurities, 
degradation products, excess raw materials, or excipients. The chromatographic method 
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should be specific and sensitive as required for all known relevant degradation products 
and/or impurities.  
(iv) Limit of detection & Limit of quantification 
The LOD of an individual analytical procedure is the lowest amount of analyte in a 
sample, which can be detected but not necessarily quantitated as an exact value. The LOQ of 
an individual analytical procedure is the lowest amount of analyte in a sample, which can be 
quantitatively determined with suitable precision and accuracy. The typical methods 
recommended by ICH to determine the LOD and LOQ are: 
(i) Signal-to-noise ratio: The LOD and LOQ can be expressed as a concentration at a 
specified signal-to-noise ratio obtained from samples spiked with analyte. 
(ii) Standard deviation of the response and the slope of the calibration curve(s) at levels 
approximating the LOD: LOD was defined as 3.3σ/S and LOQ as 10σ/S, where S is 
the slope of the calibration curve and σ is the standard deviation that can be 
determined based on the standard deviation of the blank, on the residual standard 
deviation of the regression line, or the standard deviation of y-intercepts of the 
regression lines. 
 (v)Linearity   
Linearity is the method to obtained tests that are directly proportional to the analyte 
concentration within a given range. 
A range of standards should be prepared containing at least 5 different concentrations 
of analyte, which are approximately evenly spaced, and span 80-120% of the label claim. 
 
 
Chapter 1                                                                                                                              Introduction 
 
 
J.K.K.M.M.R.F college of Pharmacy                                                    Dept of Pharmaceutical Analysis 
17 
 
Acceptance criteria: 
Correlation coefficient should be not less than 0.9990. 
% of y-intercept should be ±2.0.  % of RSD for level 1 and level 5 should be not more 
than±2.0 
 
(vi)Ruggedness 
Ruggedness is the degree of reproducibility of test results obtained by the analysis of 
the same samples under a variety of test conditions such as different laboratories, analysis, 
instruments, reagent lots, elapsed assay times, temperature, days etc. 
It can be expressed as lack influence of the operation and environmental variable on 
the test results of the analytical method. 
 (vii)Robustness 
 It is measure of capacity of an assay to remain unaffected by small but deliberate 
variation in method parameters and provide an indication of its reliability in normal usage 
degradation and variation in chromatography columns, mobile phase and inadequate method 
development are common causes of lack of robustness. 
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ABBREVIATIONS 
 
 
%                              :          Percentage 
Nm         :  Nanometre 
V/V         :      Volume by Volume 
Min                      :          Minute 
Mg         :          Milligram 
nag         :          Nano gram  
TEA                          :         Triethyl amine 
LC         :          Liquid Chromatography 
HPLC                       :          High-Performance Liquid Chromatography 
GC                            :         Gas Chromatography 
UV                            :         Ultraviolet 
HPTLC                     :         High –Performance Thin Layer Chromatography 
TLC                          :         Thin Layer Chromatography 
IPC                           :          Ion Pair Chromatography 
RPIPC                      :          Reverse Phase Ion- Pair Chromatography 
LC-MS                     :          Liquid Chromatography-Mass Spectroscopy 
FLU                          :          Fluorescence 
EC                            :           Electrochemical 
mm                           :           Millimetre 
RSD                         :           Relative Standard Deviation 
RP-HPLC                 :          Reverse Phase-High-Performance Liquid Chromatography 
RI                             :           Relative Index 
RRT                       :         Relative Retention Time 
USP                       :         United States Pharmacopoeia 
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HETP                          :         High Equivalent Theoretical Plate 
LOD                           :          Limit of Detection 
LOQ                           :          Limit of Quantification 
CV                              :         Coefficient Variance 
NMT                           :         Not More Than 
NLT                            :         Not Less Than 
R2                               :         Correlation Coefficient 
ACN                           :         Acetonitrile 
ICH                             :        International Conference of Harmonization 
Rt                                :        Retention time 
S/N                              :        Signal to Noise 
PDA                            :        Photo Diode Array Detector 
USFDA                       :        United State Food and Drug Administration 
PPM                            :        Parts Per Million 
WHO                          :        World Health Organization 
LQC                            :        Low Quality Control 
MQC                           :        Medium Quality Control 
HQC                            :       High Quality Control 
UPLC        :        Ultra Performance Liquid Chromatography 
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 AIM AND PLAN OF WORK  
Aim 
The aim of the present research work is to develop a new analytical method for the 
simultaneous estimation of paroxetine and clonazepam in tablet dosage form by Ultra 
Performance Liquid Chromatography [UPLC]. 
Objective 
The literature survey reveals that there are several methods reported for the estimation 
of paroxetine and clonazepam alone or in combination with other drugs in their 
pharmaceutical dosage forms but none of the method available for the estimation of these 
drugs in the selected pharmaceutical dosage form. 
It is not uncommon to administer two or more drugs in a single formulation, it may be 
to reduce the number of medicaments to be taken at a time for better patient compliance, to 
have broad spectrum of activity as in the case of formulations containing antimicrobial agent, 
for synergic effect or potentiating effect to reduce side effects or for quick relief. It is a 
challenging task for the analyst to develop a simple analytical method for simultaneous 
estimation of multiple drug formulations with desired degree of accuracy and precision. In 
the present work attempts have been made to develop Rapid UPLC method of analysis for a 
simultaneous estimation of selected two drugs in tablet dosage form. 
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Hence on the basis of the literature survey, it was thought to develop a precise, 
accurate, simple, rapid and reliable method for estimation of paroxetine and clonazepam drug 
in tablets using the following technique of UPLC. 
 
Plan of work was designed as follows: 
 Literature Survey 
 Study of physicochemical properties of drug (pH, pKa and solubility). 
 Procurement of chemicals and API. 
 Selection of suitable solvent. 
 Selection of suitable wavelength. 
 Development of UPLC method for the quantification of paroxetine and clonazepam in 
bulk and pharmaceutical dosage form. 
 Validation of proposed method as per ICH Q2 (R1) guidelines. 
 Estimate the amount of paroxetine and clonazepam bulk and pharmaceutical dosage 
form. 
 
 
 
Chapter 4                                                                                                                                   Literature review 
 
 
 
J.K.K.M.M.R.F college of Pharmacy                                                   Dept of Pharmaceutical Analysis 
22 
 
LITERATURE REVIEW 
Nitasha Agrawall, 2013 A reliable and sensitive high performance liquid 
chromatographic method for the determination of widely prescribed antidepressant has been 
developed. Paroxetine is a potent selective serotonin reuptake inhibitor used for the treatment 
of depression and various mood disorders. The optimum mobile phase was prepared using a 
combination of 40% acetonitrile and 60% phosphate buffer 0.01 M to pH 3 and running 
under isocratic mode at a flow rate of 1.0 ml/min. with  detection at 254nm. The applicability 
of the developed method is in the field of quality control as well as for monitoring the level of 
drug at various concentrations during synthesis of the parent drug. The suggested 
methodology was validated following the guidelines of the FDA in terms of: sensitivity 
(LOD and LOQ, 0.005 and 0.01 nag/mL, respectively), linearity between 0.5 - 50 nag/mL (r2 
> 0.9999), inter- and intraday precision (< 0.259% and < 0.538%), robustness (less than 
5.0%) and recovery (99.7 - 100.7%). The developed method is specific, rapid (less than 10 
min), precise, reliable, accurate, cheap and suitable for routine analysis for the determination 
of paroxetine in pharmaceutical preparations. 
 
Chusena Narasimharaju Bhimanadhuni, 2012, A Simple, efficient and reproducible 
reverse phase high performance liquid chromatographic method was developed and validated 
for the Simultaneous determination of paroxetine and Clonazepam in combined dosage form. 
The separation was effected on a Hypersil ODS C18 column (250mm X 4.6mm; 5µ) using a 
mobile phase mixture of buffer and acetonitrile in a ratio of 50:50 v/v at a flow rate of 
1.0ml/min. The detection was made at 240nm. The retention time of paroxetine and 
Clonazepam was found to be 2.840± 0.007min and 4.007±0.006 min.Calibration curve was 
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linear over the concentration range of 20-120µg/ml and 1-6µg/ml for paroxetineand 
Clonazepam. All the analytical validation parameters were determined and found in the limit 
as per ICH guidelines, which indicates the validity of the method. The developed method is 
also found to be precise, accurate, specific, robust and rapid for the simultaneous 
determination of paroxetine and Clonazepam in tablet dosage forms. 
 
Bhagyasree T*, et.al., 2014 A simple, precise, rapid, specific and accurate reverse phase 
high performance liquid chromatography method was developed for simultaneous estimation 
of Paroxetine and Clonazepam in pharmaceutical dosage form. Chromatographic separation 
was performed on Agilent Eclipse XDB (C) (4.6mm x 150mm, 5m) column, with mobile 
phase comprising of mixture of buffer (pH7, adjusted with ammonium acetate), acetonitrile in 
the ratio of 82:18v/v, at the flow rate 0.8 ml/min. The detection was carried out at 265 nm. 
The retention times of paroxetine and clonazepam were found to be 2.36 and 3.14 
minsrespectively with a run time of 5 mins, theoretical levels for paroxetine and clonazepam 
were 6753 and 4693 respectively, wit a resolution of 5.10. As per ICH guidelines the method 
was validated for linearity, accuracy, precision, limit of detection and limit of quantification, 
robustness and ruggedness. Linearity of paroxetine was found in the range of 100-300µg/mL 
and that for clonazepam was found to be 2-6 µg/mL. 
 
Moinuddin R Syed, 2010 A simple and reproducible method was developed for assay of 
paroxetine  in tablets. The excipients in the commercial tablet preparation did not interfere wi
th the assay. Beer’s law is obeyed in the range 2.0-10.0µg/ml at max 294 nm. The molar 
absorptivity was calculated.  Six  triplicate analyses  of  solutions  containing  six  different  
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concentrations  of  the  examined  drug  were  carried  out  and  gave  a  mean  correlation  
coefficient  0.999. The  proposed  method  was  applied  to  the  determination  of  the  
examined drug in market tablet and the results demonstrated that the method is equally accura
te, precise and reproducible as the official methods. 
 
Srinivas Reddy*, et.al., 2014 A novel stability indicating reversed-phase liquid 
chromatographic method has been developed and validated for simultaneous estimation of 
paroxetine and clonazepam in combined pharmaceutical dosage form. An Agilent zorbax sb-
c18 (250mmx4.6mmx5 µm) column with the mobile phase containing 0.2 % 
Orthophosphoric acid and Methanol (60:40 v/v) was used. The flow rate was maintained at 
0.8 ml/min, column temperature was 30°C and effluents were monitored by using a 
photodiode array detector at 270 nm. The retention times of paroxetine and clonazepam were 
found to be 3.478min and 3.964 min, respectively. Correlation co-efficient for paroxetine and 
clonazepam were found to be 0.99and 0.99, respectively. The proposed method was validated 
with respect to linearity, accuracy, precision, specificity, and robustness. Recovery of 
paroxetine and clonazepam in formulations was found to be in a range of 97-103% and 97-
103% respectively. Paroxetine and clonazepam were also subjected to the stress conditions of 
oxidative, acid, base, hydrolytic, thermal and photolytic degradation. The degradation 
products were well resolved from and peak purity test results confirmed that paroxetine and 
clonazepam peaks were homogenous and pure in all stress samples, thus proving stability-
indicating power of the method. Due to its simplicity, rapidness and high precision, this 
method can be applied for regular analysis. 
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Lakshmi Surekha G*, et.al., 2012 A simple, precise, rapid, and reproducible RP -HPLC 
method was developed and validated for the determination of Paroxetine in Pharmaceutical 
dosage form. Separation was achieved under optimized chromatographic condition on a 
PhenomenaxLunaC (ODS) column (150 X 4.6 mm i.d., particle size5m).The mobile phase 
consisted of  Phosphate buffer at pH 6.0: Acetonitrile in the ratio 50: 50 v/v. An isocratic 
elution at a flow rate of 2 ml/ min at ambient temperature. The detection was carried out at 
265 nm. Using Shimadzu UV-Visible detector SpD-10AVP.The retention time of Paroxetine 
is found to be 3.5min and the calibration curve was linear in the concentration range of 20–
100mg/ ml (r- 0.9999).The limit of detection and the limit of quantification were found to be 
0.6327 mg/ml and 1.963 mg/ml respectively. The amount of Paroxetine present in the 
formulation was found to be 99.55. The method was validated statistically using the SD, 
%RSD and SE and the values are found to be within the limits  and the recovery studies were 
performed and the  percentage recoveries was found to be 99.53± 0.6327 %. So, the proposed 
method was found to be simple, specific, linear, an drugged. Hence it can be applied for 
routine analysis of Paroxetine in the Pharmaceutical formulations.  
 
Aziz Unnisa*, et.al.,  2014 The aim of the present study is to develop RP-HPLC-PDA 
method for the simultaneous estimation of Clonazepam (CLP) and Paroxetine hydrochloride 
(PAR). The method uses a Agilent C18 reverse phase column (150 x 4.6mm, 5µm) with 
mobile phase consisting of 15mM Ammonium acetate : Methanol (40:60 v/v) at isocratic 
mode with an injection volume of 10µL and the eluents were monitored at 254nm.The 
retention times of CLP and PAR were 4.01 and 5.42 min  respectively and showed a good 
linearity in the concentration range of 1-5 µg/mL for  CLP and 25-125µg/mL for PAR with a 
good correlation coefficient for both the drugs. The validation parameters like specificity, 
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system suitability, linearity, LOD, LOQ, precision, robustness were all within the limits as 
per ICHguidelines. The proposed RP-HPLC-PDA method is specific, accurate, precise and 
economic and can be successfully applied for the simultaneous estimation of CLP and PAR 
in bulk and tablet dosage forms. 
 
Geetharam Yanamadala*, et.al.,  2014 The study describes development and subsequent 
validation of a stability indicating reverse-phase high-performance liquid chromatography 
method for the simultaneous estimation of Paroxetine hydrochloride and clonazepam in tablet 
dosage forms. A reversed-phase Kromasil ,C18, (150mm x 4.6 mm, particle size) column 
with mobile phase consisting of Acetonitrile and 0.1 % Orthophosphoric acid buffer 60:40 
(v/v) was used. The flow rate was 1.2 mLmin-1 and effluents were monitored at 260 nm. The 
retention times (RT) of Paroxetine and clonazepam were found to be 3.46 min and 4.55 min, 
respectively. The method was validated in terms of linearity, range, specificity, accuracy, and 
precision, limit of detection (LOD) and limit of quantification (LOQ). The linearity for both 
the drugs was found in the range of 125-750 µg/ml and 2.5-15 µg/ml for Paroxetine and 
clonazepam. The % recoveries of Paroxetine hydrochloride and clonazepam were found to be 
99.4 -100.6 and 98.1-101.0 respectively. The utility of the procedure is verified by its 
application to marketed formulations that were subjected to accelerated degradation studies. 
The method distinctly separated the drug and degradation products even in actual samples. 
The products formed in marketed tablet dosage forms are similar to those formed during 
stress studies.  
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Erk N*, et.al.,  2003 The antidepressant agent paroxetine hydrochloride (POT) was studied 
by cyclic voltammetry (CV),differential pulse voltammetry (DPV) and Oster young square 
wave voltammetry (OSWV). A sensitive method is described for the determination of POT in 
its pure form and in human plasma. The linear relationship between concentration and peak 
current permits the quantification of POT by CV, DPVand OSWV in the concentration range 
of 2x 10-5-8x10-4 M. Applicability to tablets and human plasma analysis has been illustrated. 
Furthermore, a HPLC method with diode array detection was developed. Linearity was 
established between 2x 10-7-6x10-5 M for POT. The described methods were successfully 
employed with high degrees of precision and accuracy for the estimation of total drug content 
in human plasma and pharmaceutical dosage forms of POT. 
 
Chakole RD*, et.al., 2012 This paper presents a RP-HPLC method for simultaneous 
estimation of paroxetine and clonazepam in pharmaceutical formulations.  The process was 
carried out on a 250 × 4.6 mm, 5µ, C18 column. The flow rate was 1ml/min and eluent was 
monitored by absorbance at 248 nm using a mixture of Methanol and Buffer (pH 4.0) in the 
ratio of 90:10 (v/v).  The retention times of paroxetineand Clonazepam was found to be 3.22 
and 4.29 min respectively.  Calibration plots were linear in the concentration range of 2.5-80 
µg mL-1 and 0.125-4 µg mL-1 for paroxetine and clonazepam respectively.  The total run 
time is 10 min.  The proposed method was validated by testing its linearity, recovery, 
specificity, system suitability, precision (Intraday and intraday), robustness andLOD/LOQ 
values and it was successfully employed for the simultaneous estimation of paroxetine and 
clonazepam in pharmaceutical tablet formulations. 
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DRUG PROFILE 
PAROXETINE 
MOLECULAR FORMULA :C19 H20FNO3 
 
MOLECULAR MASS:329.36 
 
CHEMICAL STRUCTURE 
 
MECHANISM OF ACTION 
 
Paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. It likely 
inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic 
neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its 
activity at synaptic receptor sites and potentiates 5-HT in the CNS. 
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SOLUBILITY 
It is freely soluble in methanol and ethanol, sparingly soluble in dichloro methane and 
slightly soluble in water 
PHYSICAL STATE:Off white powder 
IUPAC NAME:(3S,4R)-3-[(2H-1,3-benzodioxol-5yloxy)methyl]-4-(4- fluorophenyl)piper 
dine hydrochloride hemihydrates 
INDICATION: Major depressive disorder (MDD), panic disorder with or without 
agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), 
generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual 
dysphoric disorder (PMDD).  
PKA:                9.77  
 
 
  
ADVERSE EFFECT :  Constipation. Insomnia, blurred vision 
 
MELTING POINT:120  to 138 C 
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CLONAZEPAM 
MOLECULAR FORMULA:C15H10ClN3O3 
 
MOLECULAR MASS :315.71 
 
CHEMICAL STRUCTURE        : 
 
 
MECHANISM OF ACTION   : 
Allosteric interactions between central benzodiazepine receptors and gamma-amino butyric 
acid (GABA) receptors potentiate the effects of GABA. As GABA is an inhibitory 
neurotransmitter, this results in increased inhibition of the ascending reticular activating 
system. Benzodiazepines, in this way, block the cortical and limbic arousal that occurs 
following stimulation of the reticular pathways. 
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SOLUBILITY 
It is practically insoluble in water, slightly soluble in alcohol and methanol and very slightly 
soluble in ether. 
 
PHYSICAL STATE  :Clonazepam is slightly yellowish, crystalline powder. 
 
IUPAC NAME:5-(2-chlorophenyl)-7-nitro-2,3-dihydro-1H-1,4-benzodiazepin-2-one. 
 
INDICATION: 
Clonazepam is used as an anticonvulsant in the treatment of the Lennox-Gastautsyndrome 
(petit mal variant), alkinetic and myoclonic seizures. It can also be used for the treatment of 
panic disorders. 
PKA:11.89 
  
ADVERSE EFFECT :Drowsiness,Motor impairment, Confusion, Psychomotor agitation, 
Hallucinations. 
MELTING POINT:238° C-240° C 
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MATERIALS AND METHODS 
MATERIALS 
CHEMICALS AND WORKING REFERENCE STANDARD  
 
Paroxetine working reference standard        -Sun pharma (Sikkim India) 
 
Clonazepam working reference standard - Sun pharma (Sikkim India) 
 
PottasiumDihydrogen orthophosphate        -Merck limited(Mumbai) 
 
Ortho phosphoric acid                                  -Merck limited(Mumbai) 
 
Acetonitrile HPLC –grade                            - M/S  SD Fine chemicals (Mumbai) 
  
Methanol   HPLC –grade                            -  M/S  SD Fine chemicals (Mumbai) 
 
Water HPLC-grade                                     -Grade from Mille-QRO System. 
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EQUIPMENTS 
Instrument/Equipment’s 
used 
Makers 
UV-Visible spectrometer Shimadzu UV-2550 
UPLC Thermo scientific 
Sonicater Remi instrument Ltd 
Analytical balance 
Metler Toledo-AG204 
 
Detector 
Photodiode Array 
Detector 
pH Meter Micropro Grademate-DI707 
Analytical Column 
Thermo Fischer scientific Hypercel C18 
column (50x 2.1mm, 1.8µm). 
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METHODOLOGY 
Method development 
Selection of wavelength (λmax) 
The sensitivity of the UPLC method that uses PDA detection depends upon the proper 
selection of the wavelength. An ideal wavelength is one that gives good response for the 
drugs to be detected. In a entire UV visible region both the drugs were strongly absorbed at 
265nm. (Chromatogram no 1).So this wavelength was selected for further studies. 
Trials for RP- UPLC method development 
Trial – 1  
Chromatographic conditions 
UPLC   : Thermo Scientific UPLC system. 
Column  : Thermo Fischer scientific Hypercel C18 column (50x 
2.1mm, 1.8µm). 
Flow Rate  : 0.5 ml/min 
PDA Detection : 265nm 
Injection Volume : 5µL 
Temperature          : 25
o
C 
Run Time              : 10 min.  
Mobile phase       : Acetonitrile: Water (70:30)   
Diluent: Mobile phase. 
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Result: 
Only one drug is eluted but failed in theoretical plates and tailing factor. 
(Chromatogram no. 5) 
Trial – 2 
Chromatographic conditions 
UPLC   : Thermo Scientific UPLC system. 
Column  : Thermo Fischer scientific Hypercel C18 column (50x 
2.1mm, 1.8µm). 
Flow Rate  : 0.5 ml/min 
PDA Detection : 265nm 
Injection Volume : 5µL 
Temperature          : 25
o
C 
Run Time              : 10 min.  
Mobile phase       : Acetonitrile: methanol: Water(10:50:40)   
Diluent                : Mobile phase. 
Result: 
Both the peaks are eluted but failed in tailing factor. (Chromatogram no. 6). 
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Trial – 3 
Chromatographic conditions 
UPLC   : Thermo Scientific UPLC system. 
Column  : Thermo Fischer scientific Hypercel C18 column (50x 
2.1mm, 1.8µm). 
Flow Rate  : 0.5 ml/min 
PDA Detection : 265nm 
Injection Volume : 5µL 
Temperature          : 25
o
C 
Run Time              : 10 min.  
Mobile phase       : Acetonitrile: Methanol: Buffer (10:50:40)   
Diluent                : Mobile phase. 
Result: 
Paroxetine and Clonazepam are eluted at 1.285 and 2.458 respectively (Chromatogram no.7-
12), efficiency parameters are indicate the good separation, asymmetric. So this method was 
selected for further analysis. 
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SIMULATION ESTIMATION OF PAROXETINE AND CLONAZEPAM 
ASSAY:RP- UPLC METHOD 
CHEMICAL AND WORKING REFERENCE STANDARD 
 Paroxetine Working reference standard 
 Clonazepam working reference standard 
 Acetonitrile HPLC Grade 
 Water HPLC Grade 
TABLETS BRAND USED 
              PANZEP 
REGENTS REQUIRED 
 
272.19 mg of Potassium dihydrogen orthophosphate (2mM) was dissolved in 
sufficient water (HPLC grade) with aid ofsonicator and the volume was made up to 1000ml 
with water. Finally pH was adjusted to 3 with ortho phosphoric acid. 
MOBILE PHASE: 
Acetonitrile, Methanol and Buffer were mixed in the ratio of 10:50:40 and sonicated 
for 20minutes, Filtered with 0.45 µ membrane filter. 
DILUENT: Mobile phase. 
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STANDARD SOLUTION : 
SOLUTION (A) 
Weighed accurately 50 mg paroxetine working referenestandard  andtransferred carefully in 
to  a100ml volumetric flask sufficient mobile phase and sonicated for 10 minutes ,cooled to 
room temperature and diluted makeup with 100ml volumetric flask. 
 
SOLUTION (B) 
Weighed accurately 10 mg clonazepam working referenestandard  andtransferred carefully in 
to a100ml volumetric flask sufficient mobile phase and sonicated for 10 minutes ,cooled to 
room temperature and diluted makeup with 100ml volumetric flask. 
MIXTURED STANDARD SOLUTION: 
 
2 mL was pipetted out from the  stock solution (B) and transferred in to a 100 mL 
volumetric flask,(Solution A) diluted up to the mark with mobile phase. Then the standard 
solution with the concentration of 500µg/mL of paroxetine and 20µg/mL of Clonazepam. 
Resulting solution was then filtered with 0.45 µ membrane filter.  
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PREPARATION OF SAMPLE SOLUTIONS 
Twenty tablets were accurately weighed and finely powdered. A quantity of powder 
weight equivalent to 50mg of paroxetine and  2mg of clonazepam were weighed and 
transferred to a 100 mL volumetric flask and sufficient mobile phase was added to dissolve it. 
Then the solution was sonicated for 10 min. Final volume was adjusted with the mobile phase 
and filtered with 0.45 µ membrane filter. Then the sample solution with the concentration of 
500µg/mL of paroxetine and 20µg/mL of Clonazepam. Resulting solution was then filtered 
with 0.45 µ membrane filter.  
The amount of paroxetine and clonazepam present in each tablet were calculated by using the 
following formula: 
Amount present
=
Sample Area
Standard Area  X 
Standard  weight
Standard  Dilut ion  X 
Sample Dil
Sample weight  X Average weight  
% Amount present =
Amount present
Label Claim  X 100 
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RESULTS AND DISCUSSION 
Validation of developed method 
The developed method was validated according to ICH guidelines. The method was 
validated in terms of specificity, system suitability, linearity, precision, accuracy, robustness, 
LOD and LOQ.  
Specificity 
Specificity of the method was established by injecting the blank and placebo 
(synthetic mixtures). No interference was observed between the placebo and blank with 
principal peaks and hence the method was specific for these two drugs. 
System suitability 
System performance was determined by system suitability parameters such as retention time, 
theoretical plates,asymmetric factor and resolution were calculated and percentage RSD was 
found to be less than 2 % indicating good performance of the system (Chromatogram n7-12). 
Linearity 
Linearity of the method was established by analysis of mixed standard solution 
containing 250-750 µg/ml for Paroxetine and 10-30µg/ml for Clonazepam. The calibration 
curves drawn by plotting the response versus concentration were found to be linear and their 
coefficient of correlations (R
2
) values are 0.9993 and 0.9997 for paroxetine and Clonazepam 
respectively(Table 1& 2), indication of good correlation between concentration and responses 
(Chromatogram no13-17). 
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                                   Table 1   Linearity for Paroxetine 
concentration Sample area 
250 215843 
375 321456 
500 433557 
625 546824 
750 643974 
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Table 2   Linearity for Clonazepam 
 
 
 
 
 
 
Accuracy  
Accuracy of the method was checked by recovery studies at the level of 50%, 100% 
and 150% of known amount of Paroxetine and clonazepam were added to the placebo from 
the label claim. Paroxetine and clonazepam recovered in all the levels were found to be close 
to 100%, indicates that the accuracy of the proposed method (Table 3-8), (Chromatogram no. 
18- 26). 
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concentration Sample area 
10 99571 
15 148734 
20 197855 
25 251163 
30 298534 
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Table 3 Accuracy of Paroxetine 50 % 
Sample  area Std area Added amt Amt Recovery % Amt recovery 
218362 433294 25 25.07191307 100.2877 
219449 433294 25 25.19672036 100.7869 
221846 433294 25 25.47193938 101.8878 
  
AVG 25.2468576 100.9874 
  
SD 0.204671858 0.818687 
  
% RSD 0.810682507 0.810683 
Table 4 Accuracy of Paroxetine 100 % 
sample area Std area Added amt Amt Recovery % Amt recovery 
433621 433294 50 49.78754552 99.57509 
433527 433294 50 49.77675262 99.55351 
433612 433294 50 49.78651216 99.57302 
  
AVG 49.78360343 99.56721 
  
SD 0.005955435 0.011911 
  
% RSD 0.011962643 0.011963 
Table 5 Accuracy of Paroxetine 150 % 
Sample  area Std area Added amt Amt Recovery % Amt recovery 
653457 433294 75 75.02870049 100.0383 
657891 433294 75 75.53780401 100.7171 
657487 433294 75 75.49141749 100.6552 
  
AVG 75.35264066 100.4702 
  
SD 0.28149752 0.37533 
  
% RSD 0.373573531 0.373574 
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Table 6 Accuracy of Clonazepam 50 % 
Sample  area Std area Added amt Amt Recovery % Amt recovery 
99612 199268 5 4.958905 99.1781 
99214 199268 5 4.939091 98.78183 
99254 199268 5 4.941083 98.82166 
  
AVG 4.94636 98.92719 
  
SD 0.01091 0.218198 
  
% RSD 0.220565 0.220565 
Table 7 Accuracy of Clonazepam100 % 
sample area Std area Added amt Amt Recovery % Amt recovery 
199214 199268 10 9.917312 99.17312 
199351 199268 10 9.924132 99.24132 
199345 199268 10 9.923833 99.23833 
  
AVG 9.921759 99.21759 
  
SD 0.003854 0.038543 
  
%RSD 0.038847 0.038847 
Table 8 Accuracy of Clonazepam150 % 
Sample  area Std area Added amt Amt Recovery % Amt recovery 
298457 199268 15 14.85785 99.05231 
298075 199268 15 14.83883 98.92553 
297458 199268 15 14.80811 98.72076 
  
AVG 14.83493 98.89954 
  
SD 0.025094 0.167297 
  
% RSD 0.169158 0.169158 
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Precision 
Precision study was established by injecting the sample solution (multiple sampling of 
the same homogeneous sample)without changing the assay procedure and the results were 
presented in table 9-32. Precision may be considered at three levels: repeatability, 
intermediate precision and reproducibility 
Repeatability 
This study was performed with a minimum of six replicate measurements of sample 
solution at a same day (Chromatogram   no. 27-32). 
Intermediate Precision 
Intermediate precision was performed by injecting the sample solution in three 
different days, by different analysts and in different instruments(Chromatogram no. 33-41). 
Reproducibility 
Reproducibility of the method was checked in two laboratories and the results were 
compared.(Chromatogram no. 42-43). 
The low % RSD (< 2 %) for Paroxetine and clonazepam indicated that the method is 
precise. 
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Table 9 Evaluation of precision study [paroxetine 0hrs] 
Sample  area Std area Avgwt Amt present %  Amt present 
431257 433294 262.9 12.37902888 99.03223 
435784 433294 262.9 12.50897428 100.0718 
432175 433294 262.9 12.40537963 99.24304 
435784 433294 262.9 12.50897428 100.0718 
431278 433294 262.9 12.37963167 99.03705 
432587 433294 262.9 12.4172059 99.33765 
  
AVG 12.4331991 99.46559 
  
SD 0.060526594 0.484213 
  
% RSD 0.486814319 0.486814 
Table 10 Evaluation of precision study [paroxetine 8hrs] 
Sample area Std area Avgwt Amt present %  Amt present 
431257 433294 262.9 12.37902888 99.03223 
432157 433294 262.9 12.40486295 99.2389 
439815 433294 262.9 12.62468223 100.9975 
433756 433294 262.9 12.45076149 99.60609 
432150 433294 262.9 12.40466202 99.2373 
432517 433294 262.9 12.41519658 99.32157 
  
AVG 12.44653236 99.57226 
  
SD 0.090314316 0.722515 
  
% RSD 0.725618298 0.725618 
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  Table 11Evaluation of precision study [paroxetine 16hrs] 
sample area Std area AVG wt Amt present %  Amt present 
432165 433294 262.9 12.40509259 99.24074 
432157 433294 262.9 12.40486295 99.2389 
436844 433294 262.9 12.53940108 100.3152 
432171 433294 262.9 12.40526481 99.24212 
435274 433294 262.9 12.49433497 99.95468 
432457 433294 262.9 12.41347431 99.30779 
  
AVG 12.44373845 99.54991 
  
SD 0.05850178 0.468014 
  
% RSD 0.470130264 0.47013 
Table 12 Evaluation of precision study [Clonazepam 0hrs] 
Sample area Std area AVG wt Amt present %  Amt present 
199872 199268 262.9 0.497503 99.50068 
199147 199268 262.9 0.495699 99.13976 
199247 199268 262.9 0.495948 99.18955 
199254 199268 262.9 0.495965 99.19303 
199578 199268 262.9 0.496772 99.35432 
199587 199268 262.9 0.496794 99.35881 
  
AVG 0.496447 99.28936 
  
SD 0.00069 0.138074 
  
% RSD 0.139062 0.139062 
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Table 13 Evaluation of precision study [Clonazepam 8hrs] 
Sample  area Std area AVG wt Amt present %  Amt present 
199874 199268 262.9 0.497508 99.50168 
199324 199268 262.9 0.496139 99.22788 
199265 199268 262.9 0.495993 99.19851 
199872 199268 262.9 0.497503 99.50068 
199771 199268 262.9 0.497252 99.4504 
199358 199268 262.9 0.496224 99.2448 
  
AVG 0.49677 99.35399 
  
SD 0.000723 0.144657 
  
% RSD 0.145598 0.145598 
Table 14 Evaluation of precision study [Clonazepam 16hrs] 
sample area Std area AVG wt Amt present %  Amt present 
199257 199268 262.9 0.495973 99.19452 
199876 199268 262.9 0.497513 99.50268 
198733 199268 262.9 0.494668 98.93367 
198001 199268 262.9 0.492846 98.56926 
198745 199268 262.9 0.494698 98.93964 
199325 199268 262.9 0.496142 99.22838 
  
AVG 0.495307 99.06136 
  
SD 0.001603 0.320522 
  
% RSD 0.323559 0.323559 
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Table 15Evaluation of precision study [paroxetine Day 1] 
Sample area Std area AVG wt Amt present %  Amt present 
435781 433294 262.9 12.50888816 100.0711 
432105 433294 262.9 12.40337032 99.22696 
430178 433294 262.9 12.34805669 98.78445 
432517 433294 262.9 12.41519658 99.32157 
432014 433294 262.9 12.4007582 99.20607 
432178 433294 262.9 12.40546575 99.24373 
  
AVG 12.41362262 99.30898 
  
SD 0.052371805 0.418974 
  
% RSD 0.421889779 0.42189 
Table 16Evaluation of precision study [Clonazepam Day 1] 
Sample  area Std area AVG wt Amt present %  Amt present 
199875 199268 262.9 0.497511 99.50218 
198756 199268 262.9 0.494726 98.94512 
197546 199268 262.9 0.491714 98.34275 
198763 199268 262.9 0.494743 98.9486 
199782 199268 262.9 0.497279 99.45588 
199763 199268 262.9 0.497232 99.44642 
  
AVG 0.495534 99.10682 
  
SD 0.002268 0.453534 
  
% RSD 0.457621 0.457621 
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Table 17 Evaluation of precision study [paroxetine Day 2] 
sample area Std area AVG wt Amt present %  Amt present 
432517 433294 262.9 12.41519658 99.32157 
430214 433294 262.9 12.34909005 98.79272 
432104 433294 262.9 12.40334161 99.22673 
432017 433294 262.9 12.40084432 99.20675 
432107 433294 262.9 12.40342772 99.22742 
432117 433294 262.9 12.40371477 99.22972 
  
Avg 12.39593584 99.16749 
  
SD 0.023499288 0.187994 
  
% RSD 0.18957252 0.189573 
Table 18 Evaluation of precision study [Clonazepam Day 2] 
Sample  area Std area AVG wt Amt present %  Amt present 
198075 199268 262.9 0.49303 98.6061 
199874 199268 262.9 0.497508 99.50168 
199354 199268 262.9 0.496214 99.24281 
199842 199268 262.9 0.497429 99.48575 
198677 199268 262.9 0.494529 98.90579 
198768 199268 262.9 0.494755 98.95109 
  
Avg 0.495578 99.11554 
  
SD 0.001779 0.355789 
  
% RSD 0.358964 0.358964 
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Table 19 Evaluation of precision study [paroxetine Day 3] 
sample area Std area Avg. Wt Amt present %  Amt present 
435102 433294 262.9 12.48939779 99.91518 
435012 433294 262.9 12.48681438 99.89452 
431187 433294 262.9 12.37701956 99.01616 
435551 433294 262.9 12.50228612 100.0183 
438452 433294 262.9 12.58555796 100.6845 
435780 433294 262.9 12.50885946 100.0709 
  
AVG 12.49165588 99.93325 
  
SD 0.066927708 0.535422 
  
% RSD 0.535779316 0.535779 
Table 20 Evaluation of precision study [Clonazepam Day 3] 
Sample  area Std area Avg.wt Amt present %  Amt present 
199324 199268 262.9 0.496139 99.22788 
198752 199268 262.9 0.494716 98.94312 
198754 199268 262.9 0.494721 98.94412 
198764 199268 262.9 0.494745 98.9491 
198757 199268 262.9 0.494728 98.94561 
198756 199268 262.9 0.494726 98.94512 
  
AVG 0.494962 98.99249 
  
SD 0.000577 0.115333 
  
% RSD 0.116507 0.116507 
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Table 21 Evaluation of precision study [paroxetine Instrument 1] 
sample area Std area Avgwt Amt present %  Amt present 
432157 433294 262.9 12.40486295 99.2389 
431447 433294 262.9 12.38448274 99.07586 
432718 433294 262.9 12.42096619 99.36773 
432571 433294 262.9 12.41674663 99.33397 
435781 433294 262.9 12.50888816 100.0711 
435178 433294 262.9 12.49157933 99.93263 
  
AVG 12.437921 99.50337 
  
SD 0.050199317 0.401595 
  
% RSD 0.403598936 0.403599 
Table 22 Evaluation of precision study [Clonazepam Instrument 1] 
Sample  area Std area Avgwt Amt present %  Amt present 
199875 199268 262.9 0.497511 99.50218 
199524 199268 262.9 0.496637 99.32744 
198754 199268 262.9 0.494721 98.94412 
199436 199268 262.9 0.496418 99.28363 
198767 199268 262.9 0.494753 98.95059 
196874 199268 262.9 0.490041 98.00821 
  
AVG 0.495013 99.0027 
  
SD 0.002673 0.534604 
  
% RSD 0.53999 0.53999 
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Table 23 Evaluation of precision study [paroxetine Instrument 2] 
Sample  area Std area Avgwt Amt present %  Amt present 
435784 433294 262.9 12.50897428 100.0718 
436641 433294 262.9 12.53357406 100.2686 
438001 433294 262.9 12.57261222 100.5809 
436800 433294 262.9 12.53813808 100.3051 
432172 433294 262.9 12.40529352 99.24235 
435471 433294 262.9 12.49998976 99.99992 
  
AVG 12.50976365 100.0781 
  
SD 0.057152684 0.457221 
  
% RSD 0.456864615 0.456865 
Table 24 Evaluation of precision study [Clonazepam Instrument 2 ] 
sample area Std area Avg. wt Amt present %  Amt present 
198687 199268 262.9 0.494554 98.91077 
198756 199268 262.9 0.494726 98.94512 
198754 199268 262.9 0.494721 98.94412 
198751 199268 262.9 0.494713 98.94263 
199358 199268 262.9 0.496224 99.2448 
199357 199268 262.9 0.496222 99.24431 
  
AVG 0.495193 99.03862 
  
SD 0.0008 0.160034 
  
% RSD 0.161587 0.161587 
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Table 25 Evaluation of precision study [paroxetine Analyst 1] 
sample area Std area AVG wt Amt present %  Amt present 
432541 433294 262.9 12.41588549 99.32708 
432517 433294 262.9 12.41519658 99.32157 
430012 433294 262.9 12.34329174 98.74633 
432157 433294 262.9 12.40486295 99.2389 
436687 433294 262.9 12.53489447 100.2792 
436514 433294 262.9 12.52992858 100.2394 
  
AVG 12.44067663 99.52541 
  
SD 0.075991028 0.607928 
  
%RSD 0.610827132 0.610827 
Table 26 Evaluation of precision study [Clonazepam Analyst 1] 
sample area Std area Avgwt Amt present %  Amt present 
199687 199268 262.9 0.497043 99.40859 
199344 199268 262.9 0.496189 99.23783 
199752 199268 262.9 0.497205 99.44095 
199762 199268 262.9 0.49723 99.44592 
199325 199268 262.9 0.496142 99.22838 
196582 199268 262.9 0.489314 97.86285 
  
AVG 0.49552 99.10409 
  
SD 0.00308 0.615963 
  
% RSD 0.621531 0.621531 
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Table 27 Evaluation of precision study [paroxetine Analyst 2] 
sample area Std area AVG wt Amt present %  Amt present 
432157 433294 262.9 12.40486295 99.2389 
432510 433294 262.9 12.41499565 99.31997 
436571 433294 262.9 12.53156474 100.2525 
435781 433294 262.9 12.50888816 100.0711 
432578 433294 262.9 12.41694756 99.33558 
436871 433294 262.9 12.5401761 100.3214 
  
AVG 12.46957253 99.75658 
  
SD 0.063732206 0.509858 
  
% RSD 0.511101768 0.511102 
Table 28 Evaluation of precision study [Clonazepam Analyst 2] 
sample area Std area Avgwt Amt present %  Amt present 
198756 199268 262.9 0.494726 98.94512 
198976 199268 262.9 0.495273 99.05464 
198750 199268 262.9 0.494711 98.94213 
199024 199268 262.9 0.495393 99.07853 
199024 199268 262.9 0.495393 99.07853 
199875 199268 262.9 0.497511 99.50218 
  
AVG 0.495501 99.10019 
  
SD 0.001034 0.206707 
  
% RSD 0.208584 0.208584 
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Table 29 Evaluation of precision study paroxetine Lab 1] 
sam area Std area AVG wt Amt present %  Amt present 
430217 433294 262.9 12.34917617 98.79341 
435879 433294 262.9 12.51170121 100.0936 
435712 433294 262.9 12.50690755 100.0553 
432570 433294 262.9 12.41671792 99.33374 
432470 433294 262.9 12.41384747 99.31078 
432201 433294 262.9 12.40612595 99.24901 
  
AVG 12.43407938 99.47264 
  
SD 0.063292639 0.506341 
  
% RSD 0.509025535 0.509026 
Table 30Evaluation of precision study [Clonazepam Lab 1] 
sample area Std area AVG wt Amt present %  Amt present 
199870 199268 262.9 0.497498 99.49969 
199400 199268 262.9 0.496329 99.26571 
199330 199268 262.9 0.496154 99.23086 
199647 199268 262.9 0.496943 99.38867 
199876 199268 262.9 0.497513 99.50268 
199235 199268 262.9 0.495918 99.18357 
  
AVG 0.496726 99.3452 
  
SD 0.000693 0.138614 
  
% RSD 0.139528 0.139528 
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Table 31Evaluation of precision study [paroxetine Lab 2] 
Sample  area Std area AVG wt Amt present %  Amt present 
433628 433294 262.9 12.44708731 99.5767 
433256 433294 262.9 12.43640923 99.49127 
433158 433294 262.9 12.43359618 99.46877 
433621 433294 262.9 12.44688638 99.57509 
433281 433294 262.9 12.43712684 99.49701 
433694 433294 262.9 12.44898181 99.59185 
  
AVG 12.44168129 99.53345 
  
SD 0.006686139 0.053489 
  
% RSD 0.053739831 0.05374 
Table 32 Evaluation of precision study [Clonazepam Lab 2] 
sample area Std area AVG wt Amt present %  Amt present 
199025 199268 262.9 0.495395 99.07903 
199878 199268 262.9 0.497518 99.50367 
199644 199268 262.9 0.496936 99.38718 
199847 199268 262.9 0.497441 99.48824 
199735 199268 262.9 0.497162 99.43248 
199358 199268 262.9 0.496224 99.2448 
  
AVG 0.49678 99.3559 
  
SD 0.000822 0.164434 
  
% RSD 0.1655 0.1655 
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Robustness 
Robustness of the method was checked by small deliberate changes in the method 
parameters such as wavelength (±2nm), flow rate (±0.2ml), mobile phase ratio (±2%) and pH 
(± 0.05) but this changes, not affected the method results (Table 44-48), (Chromatogram no. 
44-51). 
The % RSD value calculated from the robustness study was found to be less than 2 % 
for Paroxetine and clonazepam, indicated that the method is robust. 
Table 33 By changing the wavelength + 1nm of paroxetine 
Sample  area Std area Avgwt Amt present %  Amt present 
433625 433294 262.9 12.4470012 99.57601 
433158 433294 262.9 12.43359618 99.46877 
433691 433294 262.9 12.4488957 99.59117 
  
AVG 12.44316436 99.54531 
  
SD 0.00834025 0.066722 
  
% RSD 0.067026765 0.067027 
Table 34 By changing the wavelength + 1nm of Clonazepam 
Sample  area Std area Avgwt Amt present %  Amt present 
199865 199268 262.9 0.497486 99.4972 
199766 199268 262.9 0.49724 99.44792 
199872 199268 262.9 0.497503 99.50068 
  
AVG 0.49741 99.48193 
  
SD 0.000148 0.029512 
  
% RSD 0.029665 0.029665 
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Table 35   By changing the wavelength - 1nm of paroxetine 
Sample  area Std area Avgwt Amt present %  Amt present 
433261 433294 262.9 12.43655275 99.49242 
433157 433294 262.9 12.43356748 99.46854 
433822 433294 262.9 12.45265599 99.62125 
  
AVG 12.44092541 99.5274 
  
SD 0.010268053 0.082144 
  
% RSD 0.082534479 0.082534 
Table 36   By changing the wavelength - 1nm of Clonazepam 
Sample  area Std area avgwt Amt present %  Amt present 
199785 199268 262.9 0.497287 99.45737 
199874 199268 262.9 0.497508 99.50168 
199586 199268 262.9 0.496792 99.35831 
  
AVG 0.497196 99.43912 
  
SD 0.000367 0.073409 
  
% RSD 0.073823 0.073823 
Table 37  By changing the flow rate +10µl of paroxetine 
sample area Std area Avgwt Amt present %  Amt present 
433871 433294 262.9 12.45406251 99.6325 
433697 433294 262.9 12.44906793 99.59254 
433965 433294 262.9 12.45676074 99.65409 
  AVG 12.45329706 99.62638 
  SD 0.003903112 0.031225 
  %RSD 0.031341999 0.031342 
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Table 38 By changing the flow rate +10µl of Clonazepam 
Sample  area Std area Avgwt Amt present %  Amt present 
199876 199268 262.9 0.497513 99.50268 
199832 199268 262.9 0.497404 99.48077 
199887 199268 262.9 0.497541 99.50815 
  
AVG 0.497486 99.4972 
  
SD 7.24E-05 0.014488 
  
% RSD 0.014561 0.014561 
Table 39 By changing the flow rate -10µl of paroxetine 
Sample  area Std area Avgwt Amt present %  Amt present 
433658 433294 262.9 12.44794845 99.58359 
432315 433294 262.9 12.40939827 99.27519 
433382 433294 262.9 12.440026 99.52021 
  
AVG 12.43245757 99.45966 
  
SD 0.020359026 0.162872 
  
% RSD 0.163757054 0.163757 
Table 40 By changing the flow rate -10µl of Clonazepam 
Sample  area Std area Avgwt Amt present %  Amt present 
199005 199268 262.9 0.495345 99.06907 
199024 199268 262.9 0.495393 99.07853 
199324 199268 262.9 0.496139 99.22788 
  
AVG 0.495626 99.12516 
  
SD 0.000445 0.089081 
  
% RSD 0.089868 0.089868 
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Table 41 By changing pH + 0.05 of Paroxetine 
Sample  area Std area Avgwt Amt present %  Amt present 
433258 433294 262.9 12.43646664 99.49173 
433197 433294 262.9 12.43471566 99.47773 
433175 433294 262.9 12.43408416 99.47267 
  AVG 12.43508882 99.48071 
  SD 0.001234295 0.009874 
  % RSD 0.009925902 0.009926 
Table 42 By changing pH + 0.05 of Clonazepam 
Sample  area Std area Avgwt Amt present %  Amt present 
199365 199268 262.9 0.496241 99.24829 
199866 199268 262.9 0.497488 99.4977 
199357 199268 262.sss9 0.496222 99.24431 
  AVG 0.49665 99.3301 
  SD 0.000726 0.14516 
  % RSD 0.146139 0.146139 
Table 43 By changing pH - 0.05 of paroxetine 
sam area Std area Avgwt Amt present %  Amt present 
433256 433294 262.9 12.43640923 99.49127 
433186 433294 262.9 12.43439991 99.4752 
433475 433294 262.9 12.44269552 99.54156 
  AVG 12.43783489 99.50268 
  SD 0.004327662 0.034621 
  % RSD 0.034794334 0.034794 
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Table 44 By changing pH - 0.05 of Clonazepam 
sample area Std area AVG wt Amt present %  Amt present 
199650 199268 262.9 0.496951 99.39017 
199057 199268 262.9 0.495475 99.09496 
198862 199268 262.9 0.494989 98.99788 
  
AVG 0.495805 99.161 
  
SD 0.001022 0.204311 
  
%RSD 0.20604 0.20604 
Table 45  By changing mobile phase + 2% of paroxetine 
Sample  area Std area AVG wt. Amt present %  Amt present 
432157 433294 262.9 12.40486295 99.2389 
435781 433294 262.9 12.50888816 100.0711 
435175 433294 262.9 12.49149322 99.93195 
  
AVG 12.46841478 99.74732 
  
SD 0.055720481 0.445764 
  
% RSD 0.446893064 0.446893 
Table 46 By changing mobile phase + 2% of Clonazepam 
Sample  area Std area AVG wt Amt present %  Amt present 
199802 199268 262.9 0.497329 99.46584 
199346 199268 262.9 0.496194 99.23883 
199863 199268 262.9 0.497481 99.4962 
  
AVG 0.497001 99.40029 
  
SD 0.000703 0.140651 
  
% RSD 0.141499 0.141499 
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Table 47 By changing mobile phase - 2% of paroxetine 
Sample  area Std area Avgwt Amt present %  Amt present 
432157 433294 262.9 12.40486295 99.2389 
432578 433294 262.9 12.41694756 99.33558 
435171 433294 262.9 12.4913784 99.93103 
  
AVG 12.43772964 99.50184 
  
SD 0.046852447 0.37482 
  
% RSD 0.37669614 0.376696 
Table 48 By changing mobile phase - 2% of Clonazepam 
Sample  area Std area Avgwt Amt present %  Amt present 
198725 199268 262.9 0.494648 98.92968 
199025 199268 262.9 0.495395 99.07903 
198738 199268 262.9 0.494681 98.93615 
  
AVG 0.494908 98.98162 
  
SD 0.000422 0.084419 
  
% RSD 0.085288 0.085288 
 
Limit of Detection (LOD) and Limit of Quantification (LOQ) 
LOD and LOQ were calculated based on the standard deviation of the response (50% 
concentration solution) and the slope of calibration graph. LOD and LOQ were found to be 
138.36 ng/ml and 419.29ng/ml for Paroxetine   74.81ng/ml and 226.72ng/ml for Clonazepam. 
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Stability 
Standard and sample Solutions stability were checked up to 3 days at room 
temperature and the Reponses was measured on one time at each day. Results revealed that, 
there was no degradation of Paroxetine and clonazepam during this period. The results were 
presented in Table 49-50. 
Table 49 Evaluation of Stability studies of paroxetine 
Sample  area Std         area Avgwt Amt present %  Amt present 
432157 433294 262.9 12.40486295 99.2389 
435712 433294 262.9 12.50690755 100.0553 
432178 433294 262.9 12.40546575 99.24373 
Table 50 Evaluation of Stability studies of Clonazepam 
sample area Std area Avgwt Amt present     %  Amt  present 
199876 199268 262.9 0.497513 99.50268 
199873 199268 262.9 0.497506 99.50118 
199876 199268 262.9 0.497513 99.50268 
 
All the validation parameters results revealed that, the developed and optimized 
method was suitable, linear, precise, accurate and robust for the simultaneous estimation of 
Paroxetineand clonazepam in pharmaceutical dosage form 
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Method application to the marketed dosage form 
 Assay was performed on marketed dosage form as per the above described procedure. 
Six replicate injections of sample solutions were given in to HPLC system without changing 
the proposed method conditions and the amount Paroxetine and clonazepam present in each 
tablet was calculated and found to be 501.64mg and 403.54mg respectively (Table 51), 
(Chromatogram no. 52) 
Table 51 Assay results for commercial formulation 
Paroxetine Clonazepam 
Amount present (mg)       Percentage (%) Amount present (mg)         Percentage (%) 
12.47 99.76 0.501 100.00 
12.52 100.00 0.492 98.40 
12.44 99.52 0.489 97.80 
12.43 99.44 0.489 97.80 
12.49 99.92 0.494 98.80 
12.54 100.32 0.499 99.80 
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CHROMATOGRAM-1 
 
Selection of wavelength 
 
CHROMATOGRAM-2 
 
 
MOBILE PHASE  
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CHROMATOGRAM-3 
 
 
REFERENCE STANDARD FOR PAROXETINE 
 
 
 
 
 
 
 
CHROMATOGRAM-4 
 
 
REFERENCE STANDARD FOR CLONAZEPAM 
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CHROMATOGRAM-5 
 
TRAIL-1 
 
 
 
 
 
 
CHROMATOGRAM-6 
TRAIL-2 
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SYSTEM SUITABILITY 
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CHROMATOGRAM NO -9 
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CHROMATOGRAM NO -10 
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CHROMATOGRAM NO -11 
 
 System suitability 5 
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CHROMATOGRAM NO -12 
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LINEARITY 
CHROMATOGRAM NO -13 
 
Linearity 50% 
Minutes
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
V
o
lt
s
0
20
40
60
80
V
o
lt
s
0
20
40
60
80
P
a
ro
x
e
ti
n
 H
c
l
C
lo
n
a
z
e
p
a
m
 
 
 
 
 
 
 
 
 
 
CHROMATOGRAM NO -14 
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CHROMATOGRAM NO -15 
 
Linearity 100% 
 
Minutes
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
V
o
lt
s
0
20
40
60
80
V
o
lt
s
0
20
40
60
80
P
a
ro
x
e
ti
n
 H
c
l
C
lo
n
a
z
e
p
a
m
 
 
 
 
CHROMATOGRAM NO -16 
 
Linearity 125% 
 
Minutes
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
V
o
lt
s
0
25
50
75
100
V
o
lt
s
0
25
50
75
100
P
a
ro
x
e
ti
n
 H
c
l
C
lo
n
a
z
e
p
a
m
 
 
 
Chapter 8                                                                                                                                           Chromatogram 
 
 
 
J.K.K.M.M.R.F college of Pharmacy                                                    Dept of Pharmaceutical Analysis 
74 
 
 
CHROMATOGRAM NO -17 
 
Linearity 150% 
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ACCURACY 
CHROMATOGRAM NO -18 
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CHROMATOGRAM NO -19 
 
Accuracy 50% [2] 
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CHROMATOGRAM NO -20 
 
 
Accuracy50% [3] 
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CHROMATOGRAM NO -21 
 
 
Accuracy 100% [1] 
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Accuracy 100% [2] 
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CHROMATOGRAM NO -23 
 
Accuracy 100% [3] 
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Accuracy 150% [1] 
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CHROMATOGRAM NO -25 
 
Accuracy 150% [2] 
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CHROMATOGRAM NO -26 
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PRECISION 
CHROMATOGRAM NO -27 
 
Repeatability 1 
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CHROMATOGRAM NO -29 
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CHROMATOGRAM NO -30 
 
 
Repeatability 4 
 
Minutes
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
V
o
lt
s
0
20
40
60
80
V
o
lt
s
0
20
40
60
80
P
a
ro
x
e
ti
n
 H
c
l
C
lo
n
a
z
e
p
a
m
 
 
 
 
 
 
Chapter 8                                                                                                                                           Chromatogram 
 
 
 
J.K.K.M.M.R.F college of Pharmacy                                                    Dept of Pharmaceutical Analysis 
81 
 
CHROMATOGRAM NO -31 
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CHROMATOGRAM NO -33 
 
 Intermediate Precision[Day 1] 
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CHROMATOGRAM NO -35 
 
 
Intermediate Precision [Day 3] 
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CHROMATOGRAM NO -36 
Precision [Analyst 1] 
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CHROMATOGRAM NO -37 
 
 
Intermediate Precision [Analyst 2] 
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Intermediate Precision [Analyst 3] 
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CHROMATOGRAM NO -39 
 
 Intermediate Precision [Instrument 1] 
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CHROMATOGRAM NO -40 
 
 Intermediate Precision [Instrument 2] 
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CHROMATOGRAM NO -41 
 
 
Intermediate Precision [Instrument 3] 
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 Reproducibility[Lab 1] 
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CHROMATOGRAM NO -43 
 
 
 Reproducibility Precision [Lab 2] 
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ROBUSTNESS 
CHROMATOGRAM NO -44 
 
Robustness (by changing wavelength +2nm) 
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CHROMATOGRAM NO -45 
 
 
Robustness (by changing wavelength - 2nm) 
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CHROMATOGRAM NO -46 
 
Robustness (by changing flow rate + 0.2nm) 
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CHROMATOGRAM NO -47 
 
 
Robustness (by changing flow rate - 0.2nm) 
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CHROMATOGRAM NO -48 
 
 
Robustness (by changing mobile phase +2%) 
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CHROMATOGRAM NO -49 
 
Robustness (by changing mobile phase -2%) 
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CHROMATOGRAM NO -50 
 
Robustness (by changing pH -0.05%) 
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CHROMATOGRAM NO -51 
 
 
Robustness (by changing pH +0.05%) 
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ASSAY 
CHROMATOGRAM NO -52 
 
Assay results for commercial formulation 
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SUMMARY, CONCLUSION AND FUTURE SCOPE 
  
The main objective of the present work is to develop a new simple UPLC   method for 
simultaneous estimation of paroxetine and clonazepam combined dosage form. 
 
Linearity of the method was established by analysis of mixed standard solution 
containing 250-750 µg/ml for Paroxetine and 10-30µg/ml for Clonazepam. The calibration 
curves drawn by plotting the response versus concentration were found to be linear and their 
coefficient of correlations (R
2
) values are 0.9993 and 0.9997 for paroxetine and Clonazepam 
respectively 
The good percentage   recovery of the  sample clearly indicates . The reproducibility 
and accuracy of  the developed method. Similarly the RSD  value for  precision  was found to 
be within  acceptable limit. 
Thus, to summarize, the proposed UPLC method of analysis was found to be accurate 
and precise, as depicted by the statistical data of analysis. The developed method is non 
tedious, with a very simple phase composition extremely small flow rate and relatively short 
run time. All these factors enable rapid quantification and simultaneous analysis of two drugs 
in bulk and pharmaceutical formulation without any excipient interference. It can therefore be 
concluded that the reported method could find practical application as an economical and 
rapid quality control tool for simultaneous analysis of the cited drugs from their combined 
dosage forms in both research and industrial quality control laboratories 
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GLOSSARY 
 Degassing: The  process  of  removing  dissolved  gas  from  the  liquid  mobile  phase  
before or during  use. Degassing  is  done  by  heating  by  vacuum  or  by  helium  
purging. 
 
 Drift:The  change  in  the  baseline  value  over  time, expressed  mathematically  as  the  
slope  of  the  least  line  squares  line  fitted  to  the  base  line  in  specified  region  
chromatogram. 
 Eluent:Mobil phase used to perform a chromatogram separation. The  liquid  that  exist  
through  a  chromatographic  column  during  a  separation. 
 Equilibration: The  process  of  bringing  a  chromatographic  solvent  (solvent, column, 
and  interactive  surface) to  a  thermally  and  chemically  stable  state, usually  indicated  
by  drift-free  base  line. 
 External standard: A separate  sample  that  contains  know  quantities  of  the  same  
compounds  that  are  in  unknown  samples. External  standards  are  used  for  
quantitation  by  matching  the  detector  response  of a component. The calibration  curve  
is generate  from  a separately  processed  standard (or  set  of  standards). 
 Fronting peak: An asymmetrically  shaped  chromatographic peak   in  which  the  front  
part  of  the  peak (before  the  apex) contains  more  area  then  the  rear  of  the  peak. 
Teasymmetry factor for fronting peak has value less then one. The opposite of fronting 
peak is a tailing peak. 
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 Fused peak: Two  or  more  no  baseline-resolved  peaks  in  a  chromatogram  that  
share  the  same  baseline, the  same  baseline  start  and  end  points, and  the  same  
slope  and  offset. 
 Elution: Also  called  as  solvent  programming  a  technique  for  decreasing  the  
separation  time  by  increasing  the  mobile  phase  strength  over  time  during  a 
chromatographicseparation. Gradients  can  be  continuous  or  stepwise. Binary (2-
solvent), ternary (3-solvent) and  quaternary  (4-solvent)  gradients  are  used  routinely  
in  HPLC. 
 Integration: The  mathematical   process  of  calculating  an  area  such  a  
chromatographic  peak  that  is  bounded  in  a  part  or  in  a  whole  by  a  curved  line. 
 Isocratic: The  condition  in  which  the  solvent  composition, flow  rate, and  the  
temperature  are  constant  during  a   chromatographic  run,  the  condition  in  which  the  
solvent  composition  is  constant  during  a  chromatographic  run. 
 Mobile phase: The  fluid (gas  or liquid) that  carries  solutes  through  a    
chromatographic  column. In  LC, the liquid  that  is  pumped  through  fluid  path  of  the   
chromatographic  system  and  into  which  the  samples  are  injected. 
 Plate Count: A measure  of  the  observed  chromatographic  resolution  based  on  its  
equivalency  to  the  number  of  theoretical  plates  that  would  provide  the  same  
resolution. 
 Tailing Factor: A  measure  of  peak  symmetry, where  a  symmetrical  peak  has  a  
tailing  factor  of 1. As tailing  increases, peak  symmetry  increases  for  system  
suitability, the  tailing  factor  is  the  width  of  the  peak  at  5% height, divided  by  two  
times  the  distance  from  the    peak  maximum  to  the  leading  edge  of  the  peak 
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(where the distance  is  measured  at  point 5% of  point  the peak  height  from  the  
baseline). 
 Acceptance Criteria: Numerical  limits, ranges, or  other   suitable  for  acceptance  of  
the  results  of  analytical procedures. 
 Drug Product: A finished  dosage  form, for example, a  capsule  tablet, or  solution  that  
contains  drug  substances, but  not  necessarily, in  association  with  one  or  more  other  
ingredients. 
 Drug Substance/Active Ingredient: An active  ingredient  that  is  intended  to  furnish  
pharmacological  active  or  other  direct  effect  the  structure  are  any  function  of  the  
human  body. The  active  ingredient  dose  not  includes  intermediates  used  in  the  
synthesis  of   such  ingredient. The  term  includes  those  components  that  may  
undergo  chemical   change  in  the  manufacture  of  the  drug  product 
 Reagent: For  analytical  procedures, any  substance  used  in  a  reaction  for  the  
purpose  of detecting, measuring, examining, or analysing  other  substances. 
 Specification: The  quality  standards (i.e., tests, analytical  procedures, and  acceptance  
criteria) provided  in  a  approved  application  to  confirm  the  quality  of  the  drug  
substances, drug products,  intermediate, raw  materials, reagents, and  other  components  
including  container  closure  systems, and  in-process  materials.  
 . Spiking: The  addition  of  a  small  known  amount  of  a  known  compound  to  a  
standard, sample, or placebo, typically  for  the  purpose  of  confirming  the  
performance  of  an  analytical  procedure  or  the  calibration  of  an  instrument. 
 Working standard: A standard  that is  qualified  against  and  used  instead  of  the  
reference  standard (also  known  as  in-house  or  secondary  standard). 
